Lipid intermediate

Lipid intermediate refers to a diverse group of bioactive molecules generated during the metabolism of fatty acids and complex lipids, including diacylglycerols (DAG), ceramides, fatty acyl-CoAs, and bacterial precursors like Lipid II (PMID: 21159780). These molecules play dual roles as essential structural components and potent signaling mediators; for instance, DAG and ceramides are involved in protein kinase C (PKC) activation and apoptotic signaling, respectively (PMID: 16477050). In the context of metabolic health, the aberrant accumulation of these intermediates in non-adipose tissues leads to lipotoxicity, which is a primary driver of insulin resistance, Type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) (PMID: 23512233). In pharmacology, specific lipid intermediates are targeted primarily in the development of antibacterial agents; for example, the cell wall precursor Lipid II is the target for glycopeptide antibiotics like vancomycin and newer agents like teixobactin (PMID: 25561178). Because Lipid intermediate describes a broad class of metabolites rather than a single discrete protein or receptor, it is generally considered a metabolic category rather than a specific therapeutic target (PMID: 21159780). The therapeutic strategy often involves modulating the enzymes that regulate these intermediates, such as ceramide synthases or diacylglycerol acyltransferases, rather than targeting the lipids themselves (PMID: 18438305).

Other names

Bioactive lipidsLipid metabolitesLipotoxic intermediatesLipid signaling moleculesMetabolic lipid precursors

Direct binding and sequestration of lipid precursors to inhibit bacterial cell wall synthesis, or pharmacological modulation of enzymes to alter the concentration of bioactive lipid intermediates in metabolic diseases.